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1. Introduction 
Behcet’s Disease (BD) is manifested by a triad of relapsing hypopyon uveitis, aphthous 
stomatitis and genital ulcers. The disease initially described by a Turkish dermatologist 
Hulusi Behcet in 1937. The etiology and pathogenesis of Behçet’s disease have not been fully 
clarified yet. However, it is now recognized as a multisystemic, immunoinflammatory 
disorder involving vessels of all sizes. The disease is most prevalent in the Mediterranean 
countries, Middle East, and Japan but has a worldwide distribution (Durmazlar et al., 2009; 
Kartal Durmazlar et al., 2008a).  
2. History and diagnosis 
The disease, currently known all over the world as “Behçet disease”, “Behçet syndrome”, 
“Behçet’s triad”, “Morbus Behçet” or “Tri-symptom Behçet” was first recognized by Dr. 
Hulusi Behçet (1889-1948) with a patient in 1924 (Tuzun, 2006; Ustun, 2002; Kartal 
Durmazlar & Kandi, 2011). This patient, who had been examined because of eye 
disturbances, recurrent oral and genital ulcers both in Istanbul and Vienna for 40 years, was 
given several diagnoses. Some doctors thought of tuberculosis or syphilis while some other 
doctors said a microorganism which was not present in Europe might have caused the 
disease. Hulusi Behçet, who continued to examine the patient after his loss of vision, 
thought that the causative agent was a virus. In the next several years he met two more 
patients with similar to that was seen in the previous patient. Hulusi Behçet thought the 
symptoms of these three patients were the symptoms of a new disease and reported his 
ideas on this topic firstly in 1936, in the Journal of Skin and Venereal Diseases (Tuzun, 2006; 
Ustun, 2002; Kartal Durmazlar & Kandi, 2011; Saylan, 1997). Later, in 1937 he wrote clear 
examples of symptomatic triad, which are still used as criterias worlwide for diagnosis of 
Behçet’s disease, in Dermatologische Wochenschrift. In the same year at the meeting of the 
Society of Paris Dermatology he declared that several factors may cause the etiology of the 
disease, which still can be an acceptable statement. Later he diagnosed further patients and 
published in German as “Tri-Symptomenkomplex” in 1939, and in English as “Triple 
symptom complex” in 1940 (Tuzun, 2006; Ustun, 2002; Kartal Durmazlar & Kandi, 2011; 
Saylan, 1997; Evereklioglu, 2006). In subsequent years, this unique disorder drew the 
attention, and the term “Behçet syndrome” was first used by Jensen in 1941 (Jensen, 1941). 
The term “Behçet disease” was first used by Fiegenbaum and Kornblueth in 1946 (Kartal 
Durmazlar & Kandi, 2011; Figenbaum, 1946; Dilsen, 1996; Alpsoy, 2009).  On 13 September 
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1947, international dermatologic societies came together in Zurich and named the disease as 
“Morbus Behçet”, which honored the first describer of “triple symptom complex” after 
Zurich Medical Faculty Professor Mischner’s proposal. In fact, several authors before Hulusi 
Behçet described one or several individual findings of this disorder. Among these 
physicians, for example, Hippocrates in the fifth century BC reported some individual 
symptoms attributed to an originally endemic and epidemic disease. But, due to sporadic 
appereance of the disease in the course of time, the disease became less significant and was 
forgotten. There were also other physicians who described one or several individual 
findings of this disorder, for example, Janin (1772), Reis (1906), Blüthe (1908), Gilbert (1920, 
1921, 1923), Planner and Remenowsky (1922), Weve (1923), Shigeta (1924), Adamantiades 
(1930), Dascalopoulos (1932), Whitwell (1934), Nishimura (1936), Blobner (1937) reported 
several individual findings of this disorder.  However, all these papers ascribed the findings 
either to another disease, such as tuberculosis, syphilis, sepsis or allergy, or to a coincidence 
and none of them indicated a new or a single syndrome with “classical triad” (Kartal 
Durmazlar & Kandi, 2011; Alpsoy 2009; Evereklioglu, 2006, 2007a, 2007b, 2007c; 
Freigenbaum, 1956). The disease is sometimes named as Adamantiades-Behcet’s disease, 
however, Behcet’s disease should be preferred as suggested by International Associations 
and Societies of “Behcet” (Mendes et al., 2009).  
Several diagnostic criteria have been developed during the years, all have in common the 3 
major features of oral ulceration, genital ulceration and eye lesion (16). Today, International 
Study Group criteria for the diagnosis of Behcet’s disease is used worldwide (Table 1) 
(International Study Group diagnostic criteria, 1990.). 
 
Recurrent oral 
ulceration 
Minor aphthous, major aphthous, or herpetiform ulceration 
observed by physician or patient recurring at least three times 
in one 12-month period 
Plus any two of the following: 
Recurrent genital 
ulceration 
Aphthous ulceration or scarring, observed by physician or 
patient 
Eye lesions Anterior uveitis, posterior uveitis, cells in the vitreous on slit-
lamp examination; or retinal vasculitis observed by 
ophthalmologist 
Skin lesions Erythema nodosum observed by the physician or patient, 
pseudofolliculitis, papulopustular lesions; or acneiform 
nodules observed by physician in post adolescent patients not 
on corticosteroids treatment 
Pathergy Read by physician at 24-48 hours (The test is performed by 
introducing a 20-gauge or smaller sterile needle 5 mm 
obliquely into the patient’s flexor aspect of the avascular 
forearm skin without injection of saline under sterile 
conditions. The test is considered positive if there is an 
indurated erythematous small papule or pustule formation of 
more than 2 mm in diameter. 
*Findings applicable only in the absence of other clinical explanations 
Table 1. International Study Group diagnostic criteria, 1990. 
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As a systemic disease, Behcet’s disease involves visceral organs also such as the 
gastrointestinal tract, pulmonary, musculoskeletal, and neurological systems (Table 2) 
(Evereklioglu, 2005).  
 
Manifestations  Characteristics 
Articular 
manifestations 
Non-migratory monoarthritis or oligoarthritis, rarely polyarthritis, 
characterized by non-specific inflammatory-type synovitis. Favors 
large joints such as the knee (most commonly), ankle, wrist, and elbow 
as well as proximal interphalangeal and metacarpophalangeal joints. 
Spinal and sacroiliac involvements are uncommon. Symptoms and 
signs: arthralgia, tenderness, swelling, limitation of joint movement, 
warmth, morning stiffness, and redness at the articular site 
Audio-
vestibular 
features 
Inner ear involvement cochlear and peripheral vestibular 
disturbances, tinnitus, deafness, dizziness, unilateral or bilateral 
sensorineural hearing, orthostatic disequilibrium 
Thoracic 
involvement 
Aorta and pulmonary artery aneurysms, infarct and hemorrhage, 
pleural effusion, pulmonary thromboembolism, tracheobronchial 
ulcerations, pneumonitis, mediastinitis, paranchymal fibrosis, 
arteriobronchial fistula, cor pulmonale, hilar and mediastinal 
lymphadenopathy, and lobular perfusion defects. Symptoms: 
hemoptysis, cough, dyspnea, and pleuritic chest pain 
GIS 
involvement  
 
Ulcerative lesions especially terminal ileum, cecum, occasionally in 
esophagus and stomach.  
Symptoms: anorexia, dysphagia, dyspepsia, vomiting, flatulence, vague 
abdominal discomfort, distention and pain, bloating, and diarrhea. 
Perforation can occur and malabsorbtion is common 
Vascular 
involvement 
Superficial and deep obliterative thrombophlebitis in lower extremity, 
varices, embolization, infarction, bleeding ulcers. Veins are affected 
more frequently than arteries. Large vessel thromboses in superior 
and inferior vena cava with a caput medusa, deep femoral and 
subclavian veins can occur. Occasionally, aorta, carotid, and popliteal 
aneurysms, radial artery occlusion, and thromboses of the hepatic 
(Budd-Chiari syndrome), mesenteric, pulmonary, iliac and renal veins 
with intracranial hypertension, mesenteric artery aneurysm 
Cardiac 
involvement 
Coronary artery disease, myocardial infarction, endocarditis, 
myocarditis, pericarditis, aortitis, valvular disease (aortic/mitral 
regurgitation), intracardiac thrombus, endomyocardial fibrosis, 
arrhythmia 
Renal 
involvement 
Microscopic hematuria and proteinuria (microalbuminuria) with 
normal renal functions, or rapidly progressive anti-neutrophylic 
antibody-associated vasculitis, cresentic or proliferative 
glomerulonephritis (focal segmental or sclerosing, diffuse or 
mesangial), IgA nephritis, renal vein thrombosis, amyloidosis, 
nephrotic syndrome, renal failure 
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Genitourinary 
involvement 
Inflammation of the testis, typically epididymitis with painful 
swelling or uncommonly orchiepididymitis, urethritis, cystitis, 
voiding dysfunction 
CNS 
involvement 
5–10% of patients are affected. Focal or multifocal parenchymal , 
peripheral or CNS involvement with both motor and sensory 
manifestations, migraine-like headache (most frequent initial sign), 
hemiparesis, behavioral changes, stiff neck, pyramidal and 
extrapyramidal signs, cerebellar ataxia, cerebral vein thrombosis, 
isolated cerebral sinus thrombosis, cranial nerve palsies, peripheral 
neuropathy, seizures, benign intracranial hypertension, life-
threatening brainstem and spinal cord lesions, aseptic meningitis, 
chronic meningoencephalitis, multiple sclerosis-like illness, organic 
confusional syndrome, acute myelitis, aneurysms, stroke, and pseudo-
tumor cerebri.  
Psychosomatic 
status 
Character disorders, aggressiveness, anxiety, depression, dementia, 
cognitive deficits, memory disturbances, impairment in 
acquisition/information storage, personality change, attention deficit, 
bipolar disorder, and chorea 
CNS _ central nervous system; GIS _ gastrointestinal system. 
Table 2. Additional Systemic Features of Behcet Disease (From Evereklioglu, 2005).  
3. Vascular involvement in Behcet’s disease 
Vasculo-Behcet Disease (VBD), which involves the arterial and venous system, is found in 
15-38% of patients with BD. Three major manifestations of VBD have been identified: 
venous occlusion, arterial occlusion and aneurysm formation, with a clear preponderance 
of the venous lesions compared to arterial involvement. The coexistence of arterial and 
venous involvement is not frequent and is one of the major causes of morbidity and 
mortality. Venous involvement, including superficial thromboflebitis and deep venous 
thrombosis, is a characteristic manifestation. Thrombosis of superficial and deep vein is 
more frequent than arterial aneurism and thrombotic occlusions (Kartal Durmazlar et al., 
2008a, 2009; Houman et al., 2001; Aksoy et al., 2010). Venous thrombosis appeared to be 
the major vascular involvement reported in 7 to 33% of cases with BD with a male 
predominance, and representing 85 to 93% of VBD (Houman et al., 2001). Deep vein 
thrombosis is seen in about one-fifth of Turkish patients with BD (Gul et al., 1999). Lower 
extremities is the most frequent site of thromboses but thromboses of other venous sites 
such as superior and inferior vena cava, coronary, portal, renal and pulmonary veins have 
been identified (Houman et al., 2001; La Regina et al., 2010). Leg ulcers in BD, which may 
be caused by vasculitis or deep vein thrombosis, have a chronic recurrent course and are 
refractory to treatment (Jung et al., 2008; Kartal Durmazlar et al, 2008b; Akgul & Kartal 
Durmazlar, 2008). 
4. Pathogenesis of Behcet’s disease and thrombosis 
The main pathology in BD is an inflammatory process of small arteries and veins and 
thrombosis as a result of vasculitis of the vaso vasorum (Evereklioglu et al., 2002). 
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Histopathological studies revealed cellular infiltrations consisting of lymphocytes, 
plasmocytes, monocytes and PMN in varying degrees, depending on the stage of lesion in 
BD. Since cytokines are involved in the regulation of functions of lymphocytes and 
phagocytes, they are playing important role in the pathogenesis of the disease (Durmazlar et 
al, 2009). Chemotactic and phagocytic activity of neutrophils in patients with BD has been 
reported to be high (19). Increased spontaneous secretion of Tumor necrotizing factor (TNF-
α), Interleukin-6 (IL-6) and Interleukin-8 (IL-8) in monocyte cultures obtained from BD 
patients have been reported (Mege et al., 1993). IL-8 secretion after incubation of human 
dermal microvascular endothelial cells with serum of BD patients indicates that chemotaxis is 
an initial process of inflammation. IL-8 upregulates neutrophil chemotaxis as mRNA 
expression have been reported to be more prominent in patients with active BD than in 
patients with inactive disease (Evereklioglu, 2005). IL-8, a major chemokine known as neutrofil 
activating factor, attract and activate leukocytes has been assumed to represent such a notable 
link between immune system activation and endothelial alterations in BD (Durmazlar et al., 
2009; Evereklioglu, 2005; Tursen, 2009). It has been suggested that Th1 type cytokines and 
chemokines including IL-17, largely produced by activated CD4+ and CD8+ T cells, are 
involved in the recruitment of neutrophils to the site of inflammation. Activated neutrophils in 
BD patients produce significant quantities of IL-12 and IL-18 (Pay et al., 2007).  
The pathogenesis of thrombotic events in BD is not fully understood. The primary 
abnormalities of the coagulation, anticoagulation, or fibrinolytic systems have not been 
confirmed yet in BD. The main factor responsible for the increased frequency of thrombosis 
in BD is thought to be endothelial dysfunction caused by vascular inflammation 
(Evereklioglu, 2005). There is accumulating evidence for inflammation markers as a result of 
thrombosis. Deep vein thrombosis significantly associates with the male gender and a 
positive pathergy test (Houman et al., 2001). A number of studies have explored the 
pathogenesis of thrombophilia in Behçet’s disease. Neither deficiency in protein C, in 
protein S, in factor V Leiden and in antithrombin III nor resistance to activated protein C 
and anticardiolipin antibody levels seem to be correlated with vascular thrombosis in 
Behçet’s disease (Houman et al., 2001; Espinosa et al., 2002; Hirohata & Kikuchi, 2003). In 
BD, there is an occlusive inflammatory thrombus formation, strictly adherent to inflamed 
vessel wall, which is typically not complicated with thromboembolism (Lakhanpal et al., 1985; 
Kobayashi et al., 2000; Matsumoto et al., 1991). There are increased thrombin generation, 
fibrinolysis, and thrombomodulin in Behçet’s disease, but these abnormalities are not related 
to thrombosis (Espinosa et al., 2002). These results therefore suggest that thrombophilia in 
Behçet’s disease may be related more to inflammation than to clotting disorder (Hirohata & 
Kikuchi, 2003). Studies have disclosed the occurrence of antiendothelial cell antibodies, 
increased E-selectin and myeloperoxydase expression in Behçet’s disease (Houman et al., 2001; 
Espinosa et al., 2002; Hirohata & Kikuchi, 2003). As neutrophils from active Behçet’s disease 
release increased amounts of myeloperoxydase, it is probable that neutrophil activation as well 
as the expression of antiendothelial cell antibodies may play an important role in the 
development of endothelial inflammatory damages, leading to thrombophilia (Houman et al., 
2001; Espinosa et al., 2002; Hirohata & Kikuchi, 2003). Figure 1 summarizes the 
immunopathogenesis of Behcet’s disease (Pay et al., 2007). 
Homocysteine (Hcy) is an intermediary sulphydryl-containing aminoacid formed during 
the conversion of methionine to cysteine. Its sulphydryl group can cause direct endothelial 
cytotoxicity, inhibition of glutathione peroxidase and nitric oxide, interference with clotting 
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APC
NeutrophillT Cell
IL – 1
IL – 18 
VIRAL / BACTERIAL ANTIGENS (HSV – 1, Sangius, Mycobacteries)
SUPERANTIGENS (Staphillococcus)
AUTOANTIGENS (HSP60, HSP70, αβ-crystallin, Retinal S, α-enolase)
HLA – B51
TNF
MICA
KIR MEFV
IL18 – IL12
IL8 – IL17
INFLAMMATION 
THROMBOSIS 
TISSUE DAMAGE
ENDOTHELIAL DYSFUNCTION
COAGULATION & FIBRINOLYTIC SYSTEM ABNORMALITIES 
(ICAM-1, eNOS, Factor V)
 
APC: Antigen presenting cell, MICA: MHC class I related gene, eNOS: Endothial NO synthetase, 
ICAM-1: intracellular adhesion molecule-1 
Fig. 1. Immunopathogenesis of Behcet’s disease  (From Pay et al., 2007). 
factor, and LDL oxidation (Kartal Durmazlar et al., 2008a, 2009). The association between 
Hcy levels and endothelial dysfunction and its correlation to the degree of endothelial 
damage have been shown in patients with BD. Hcy is thought to induce proinflammatory 
cytokines.  Suggested mechanisms of Hcy in promoting such a clotting cascade are the 
inactivation of protein C, activation of coagulation factor V, and inhibition of 
thrombomodulin (Kartal Durmazlar et al., 2008a, 2009). The increase in Hcy concentration in 
patients at risk for vascular disease is expressed as odds ratio and for venous thrombosis, 
this odds ratio is approximately 1.6. In a study, a change of 1 µmol/l in Hcy concentration 
was found to correspond to a risk ratio of 1.01 (Willems et al., 2006). A study reported that 5 
µmol/l increase of Hcy was associated with a 60% and 27% increased risk of venous 
thrombosis in retrospective and prospective studies, respectively (Omar et al., 2007). The 
association between Hcy levels and endothelial dysfunction and its correlation to the degree 
of endothelial damage has been shown in patients with BD (Ozdemir et al., 2004). Hcy 
generates superoxide and hydrogen peroxide, both of which have been linked to endothelial 
damage (Er et al., 2002). Hcy-induced vascular problems are thought to be multifactorial, 
including direct Hcy damage to the endothelium, enhanced lipid peroxidation and 
increased platelet aggregation by the effects on the coagulation system (Er et al., 2002; 
Sarican et al., 2007). Hcy has been shown in vivo and in vitro to promote inflammatory 
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process such as the adhesion of neutrophils to endothelial cells as well as the release of the 
inflammatory cytokine IL-8 and monocyte chemoattractant protein-1 (MPC-1) (Koga et al., 
2002). Hcy was shown to enhance the cytokine-stimulated expression of endothelial cell 
adhesion molecules and monocyte and T-cell adhesion to endothelial cells (Koga et al., 
2002). Hcy was shown to promote TNF-α mediated induction of vascular cell adhesion 
molecule-1 (VCAM-1) in endothelial cells (Silverman et al., 2002). Some studies have shown 
hyperhomocysteinemia as a correctable risk factor for thrombosis in BD (Kartal Durmazlar 
et al., 2008a, 2009; Omar et al., 2007; Ozdemir et al., 2004; Er et al., 2002; Sarican et al., 2007). 
In a recent work, thrombogenesis in BD is discussed through the concept of Virchow’s triad 
of venous thrombosis (La Regina et al., 2010). Based on this concept; abnormal blood flow, 
abnormal vessel wall, abnormal blood constituents are presented in Table 3.  
 
Blood flow 
abnormalities  
 
Enhanced erythrocyte aggregation, increased fibrinogen, high blood 
viscosity 
Impaired microcirculation 
Turbulent blood flow at sites of venous varices and arterial aneurysms 
Arterial and venous occlusion
Abnormal 
vessel wall 
Perivasculitis
Endothelial dysfunction 
Venous varices 
Aneurysms and pseudoaneurysms 
Abnormal 
blood 
constituents 
Endothelial factors such as  vWF, t-PA, thrombomodulin, NO, VEGF, 
endothelin-1 
Procoagulant factors  such as factor V Leiden and prothrombin 
mutations, 
hyperhomocystenemia, factors VIII, IX, lipoprotein a 
Factors of fibrinolysis such as PAI-1, t-PA 
Anticoagulant factors (protein C, S, Z,  antithrombin) 
vWF: von Willebrand factor, t-PA: tissue plasminogen activator, NO: nitric oxide, VEGF: vascular 
endothelial growth factor, PAI-1: the type-1 inhibitor of plasminogen activators, t-PA: tissue 
plasminogen activator 
Table 3. Thrombogenesis in Behcet’s Disease according to Virchow’s triad of venous 
thrombosis (From La Regina et al., 2010). 
5. Medical management of Behcet’s disease 
The choice of treatment is generally based on the clinical presentation and the site affected. 
Although the treatment has become much more effective in recent years, BD still associates 
with severe morbidity and considerable mortality. Therefore, the main aim of the treatment 
should be the prevention of irreversible organ damage, especially, during the early, active 
phase of the disease. Male sex and a younger age of onset have been reported to be 
associated with severe disease, which in case may require aggressive treatment (Alpsoy & 
Akman, 2009).Recently, a group of experts developed recommendations for the 
management of BD by combining the current evidence from controlled trials (Hatemi et al., 
2008). The European League against Rheumatism (EULAR) recommendations are 
summarized in Table 4. 
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Eye disease  Affecting the posterior segment: Azathioprine and 
local and systemic corticosteroids 
 If refractory eye involvement (retinal vasculitis or 
macular involvement):  Cyclosporine A or 
infliximab in combination with azathioprine and 
corticosteroids or  IFN-a alone or with 
corticosteroids 
Major vessel disease* 
 
 Acute deep vein thrombosis: Corticosteroids, 
azathioprine, cyclophosphamide or cyclosporine A 
 Thrombosis of the vena cava and Budd–Chiari 
syndrome: Cyclophosphamide 
 Pulmonary and peripheral arterial aneurysms: 
Cyclophosphamide and corticosteroids; surgery  
 Anticoagulants, antiplatelet and antifibrinolytic 
agents are not recommended ( there are no controlled 
data on, or evidence of benefit from uncontrolled 
experience with anticoagulants, antiplatelet or 
antifibrinolytic agents in the management of deep 
vein thrombosis pulmonary embolism is rare and 
there is the risk of major bleeding in case there are 
concomitant pulmonary aneurysms) 
Gastrointestinal involvement** 
 
Sulfasalazine, corticosteroids, azathioprine, TNF-a 
antagonists or thalidomide; surgery 
Articular involvement 
 
Colchicine; IFN-a, azathioprine, TNF-a antagonists in 
resistant cases 
CNS involvement*** 
 
 Parenchymal disease: Corticosteroids, IFN-a, 
azathioprine, cyclophosphamide, methotrexate, 
TNF-a antagonists 
 Dural sinus thrombosis: Corticosteroids 
 Cyclosporine should be avoided in case of 
neurological involvement due to neurotoxicity, 
unless necessary for intraocular inflammation. 
Mucocutaneous involvement 
(oral, genital and skin lesions) 
 Isolated lesions: Topical measures such as 
corticosteroids preparations, lidocaine gel, 
chlorhexidine, sucralfate suspension 
 Acne-like lesions:  Topical measures as used in acne 
vulgaris  
 Erythema nodosum: Colchicines 
 Resistant cases: Azathioprine, IFNa and TNFa 
antagonists may be considered in resistant cases. 
CNS: Central nervous system; IFN: Interferon; TNF: Tumour necrosis factor. 
* There is no firm evidence to guide the management of major vessel disease in BD 
** There is no evidence-based treatment that can be recommended for the management of 
gastrointestinal involvement of BD 
*** There are no controlled data to guide the management of CNS involvement in BD 
Table 4. EULAR recommendations for treatment of Behcet’s disease (Hatemi et al., 2008) 
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6. Conclusion 
The pathogenesis of thrombotic events in BD is not fully understood. The primary 
abnormalities of the coagulation, anticoagulation, or fibrinolytic systems have not been 
confirmed yet in BD. In this review current knowledge of venous thrombosis in BD are 
summarized. There is no agreement on the treatment of thrombosis in BD. However, in 
general immunosuppressive agents such as corticosteroids, azathioprine, cyclophosphamide 
or cyclosporine  are recommended for the treatment of venous thrombosis in BD. There is 
no enough evidence of benefit with anticoagulants or fibrinolytic agents in the management 
of thrombosis of BD (La Regina et al., 2010). Further studies are needed to clarify the safety 
and effectiveness of antithrombotic therapy in BD. However, owing to the complications of 
established thrombus, it would be reasonable to target different steps of the coagulation 
cascade for the prophylaxis and treatment of thrombosis in BD.  
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